arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

AMGEN INC

AMGN
$410.89 ▲ +5.98 (+1.48%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
20 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
74
Health
Good
Moderately Bullish
auto_awesome

Analytical Summary

AMGEN INC shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $221.1B
Dividend Yield 2.35%
Revenue Growth 10.0%
Op. Margin 24.7%
ROIC 12.3%
FCF / Share $15.06
Trailing P/E 28.7x
Price / Book 25.6x
FCF Yield 3.7%
Debt / Equity 6.31
info Valuation on last close. End-of-day price, Aug 7, 2026.

20-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$36.75B
↑ +10.0%
Net Income Profit after all expenses
$7.71B
↑ +88.5%
Operating Margin Operating profit as % of sales
24.7%
↑ +13.8% 81th
FCF / Share Free cash flow per share
$15.06
↓ -22.2%
Long-Term Debt Long-term obligations
$54.60B
↓ -9.1%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
83
Returns
99
Financial Health
35
Cash Quality
68

Dividend History

Dividend / share · sourced from SEC filings
$9.66 Latest / share
+5.8% YoY
+28.5% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 20 years · 74 quarters